Optibrium Expands US and UK Operations
Dr Scott Lyon, Director of BD, Optibrium
Optibrium, a developer of software for small molecule drug discovery, announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK.
Optibrium’s move to larger premises is driven by the company’s rapid recent growth and will accommodate future expansion plans as it accelerates its R&D pipeline and extends research into new technologies to improve the efficiency and productivity of the drug discovery process. In the last year Optibrium has grown by 60%, expanding its computational chemistry, software development and application science teams.
As part of this growth strategy, Dr. Scott Lyon joins Optibrium on the west coast of North America, where he has responsibility for supporting the company’s existing client base and for developing new business opportunities for StarDrop and the company’s range of products for small molecule design, optimisation and data analysis. Scott brings 20 years of experience in business development and support for scientific software and services, having previously worked at organisations including MDL, CambridgeSoft and Thomson Reuters. He has BSc from Carnegie Mellon University and a PhD in Chemistry from the University of Arizona.
Dr Matthew Segall, Optibrium’s CEO, commented: “As we move to larger, custom-designed offices, it is encouraging to see that our ongoing investment in the best scientists and engineers, who deliver cutting-edge features to our users, has resulted in strong revenue growth and thus sets the foundations for further expansion.
“We are pleased to welcome Scott to the US team and look forward to him developing our west coast community, building on our success by providing local support to our clients and maintaining Optibrium’s reputation for excellence in customer service.”
Dr Scott Lyon added: “Optibrium’s unique drug discovery software and dedication to its clients offers a great opportunity to build for success. I am delighted to join the team and contribute to the company’s further development.”
A new chemical synthesis strategy to harvest the rich information found in natural products has led to the identification of novel, simpler derivatives with potential to selectively protect neurons, important for neurodegenerative diseases like Alzheimer’s disease, or to prevent the body’s immune system from rejecting organ transplants, according to a Baylor University-led study.READ MORE